1 / 14

Aggressive Hyperglycemia Management

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up. Hyperglycemic patients Post-discharge. Previously diagnosed diabetes and elevated A1C. Without previously diagnosed diabetes (with random BG >125 mg/dL).

amanda-hatfield
Télécharger la présentation

Aggressive Hyperglycemia Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aggressive Hyperglycemia Management

  2. Significant hospital hyperglycemia requires close follow-up Hyperglycemic patients Post-discharge Previously diagnosed diabetes and elevated A1C Without previously diagnosed diabetes(with random BG >125 mg/dL) Pre-admission diabetes care plan requires revision Test (FBG, 2-hr OGTT) to differentiate between in-hospital hyperglycemia and T2DM once patient is metabolically stable Clement S et al. Diabetes Care. 2004;27:553-91. Conaway DLG et al. Am Heart J. 2006;152:1022-7.

  3. Glucose control in ACS patients with diabetes often unknown or undertreated at discharge N = 235 with diabetes + ACS Diabetes therapy adjusted A1C Patients (%) (<7%) (n = 235) (n = 39) (n = 58) (n = 162) Yes No Conaway DLG et al. Am Heart J. 2006;152:1022-7.

  4. EPIC-Norfolk: CV risk increases with A1C level N = 10,232 Women Men Events/ 100 persons <5 5–5.4 5.5–5.9 6–6.4 6.5–6.9 ≥7 <5 5–5.4 5.5–5.9 6–6.4 6.5–6.9 ≥7 A1C (%) CVD events All deaths 1% A1C associated with: 20% CVD events, 22% mortality PTrend < 0.001 across A1C categories for all endpoints Khaw K-T et al. Ann Intern Med. 2004;141:413-20.

  5. UKPDS 33: Glycemic control declines over time N = 3867 with newly diagnosed T2DM 9 8 7 6 0 A1C, median (%) ADA target 6.2% (upper limit of normal) 0 3 6 9 12 15 Years from randomization Diet (conventional treatment) Sulfonylurea or insulin (intensive treatment) UKPDS Group. Lancet.1998;352:837-53.

  6. Need for insulin increases over time UKPDS 57: N = 826 with newly diagnosed T2DM 60 40 Patients requiring additional insulin (%) 20 0 1 2 3 4 5 6 Years from randomization Chlorpropamide Glipizide ~53% of patients required additional insulin therapy by year 6 Wright A et al. Diabetes Care. 2002;25:330-6.

  7. UKPDS 33: Effect of intensive glucose control on T2DM complications P = 0.029 P = 0.34 P = 0.44 P = 0.052 P = 0.0099 Relative risk reduction (%) P = 0.52 AnyT2DM-related endpoint T2DM-related death All deaths MI Stroke Micro-vascular endpoints A1C 7% vs 7.9% with intensive vs conventional treatment All P values vs conventional treatment UKPDS Group. Lancet. 1998;352:837-53.

  8. UKPDS 34: Glucose control and CV outcomes n = 1704 overweight with T2DM; n = 342 metformin group Favors metforminor intensive Favors usual care Aggregate endpoint P* All-cause mortality Metformin Intensive MI Metformin Intensive Stroke Metformin Intensive 0.02 0.12 0.03 0 1 2 Relative risk(95% CI) *Metformin vs other intensive (sulfonylurea or insulin) UKPDS Group. Lancet. 1998;352:854-65.

  9. Limitations of UKPDS • Small difference in A1C between intensive and conventional groups: 7.0% vs 7.9% • A1C exceeded current ADA <7% target • Delay in adding multiple therapies • Insufficient power to assess CV outcomes Hypothesis-generating study UKPDS Group. Lancet. 1998;352:837-53.

  10. DCCT/EDIC: Intensive glucose control associated with reduced long-term CV risk N = 1441 with type 1 diabetes, mean baseline age 27 52 events 0.12 0.12 57% Risk (12%–79%) P = 0.02 42% Risk (9%–63%) P = 0.02 0.10 0.10 0.08 0.08 CV death, nonfatal MI, stroke* Any initial CV event* 25 events 0.06 0.06 0.04 0.04 31 events 11 events 0.02 0.02 0 0 0 5 10 15 20 0 5 10 15 20 Time (years) DCCT ends DCCT ends A1C 7.4% vs 9.1% Conventional Intensive DCCT/EDIC Study Research Group.N Engl J Med. 2005;353:2643-53. *Cumulative incidence

  11. EDIC year 11: Patient characteristics at mean age 45 *BP ≥140/90 mm Hg; †LDL-C ≥130 mg/dL ‡P < 0.01 vs intensive treatment DCCT/EDIC Study Research Group. N Engl J Med. 2005;353:2643-53.

  12. Glycemic control and vascular disease in T2DM N = 4472; 6 randomized trials Favors intense glycemic control Favors conventional glycemic control Any macrovascular*T2DM Cardiac† T2DM Peripheral vascular‡ T2DM Cerebrovascular§ T2DM 0.81 (0.73–0.91) 0.91 (0.80–1.03) 0.58 (0.38–0.89) 0.58 (0.46–0.74) 2 0 0.5 1 Incidence rate ratio(95% CI) *1587 events; †1197 events; ‡87 events; §303 events Stettler C et al. Am Heart J. 2006;152:27-38.

  13. Diabetes management trials: Clinical trial horizon UKPDSDCCT/EDIC PROactive DREAM Look AHEAD NAVIGATORVADT HEART 2D BARI 2D RECORD ADVANCE ORIGINACCORD 2012 1995-2006 2007 2008 2009 2010

  14. Ongoing trials of glucose lowering and CV outcomes A1C target (%) National Institutes of Health (NIH). www.clinicaltrials.gov Buse JB, Rosenstock J. Endocrinol Metab Clin N Am. 2005;34:221-35. *FPG is glycemic target for intervention group

More Related